These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20670195)

  • 1. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-activated receptor-1 antagonists: focus on SCH 530348.
    Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
    Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCH 530348: a novel oral thrombin receptor antagonist.
    Bonaca MP; Morrow DA
    Future Cardiol; 2009 Sep; 5(5):435-42. PubMed ID: 19715408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
    Macaulay TE; Allen C; Ziada KM
    Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atopaxar. A novel player in antiplatelet therapy?
    Wurster T; May AE
    Hamostaseologie; 2012; 32(3):228-33. PubMed ID: 22859265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel and orally active thrombin receptor antagonist E5555 (Atopaxar) inhibits arterial thrombosis without affecting bleeding time in guinea pigs.
    Kogushi M; Matsuoka T; Kawata T; Kuramochi H; Kawaguchi S; Murakami K; Hiyoshi H; Suzuki S; Kawahara T; Kajiwara A; Hishinuma I
    Eur J Pharmacol; 2011 Apr; 657(1-3):131-7. PubMed ID: 21300059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist.
    Capodanno D; Dharmashankar K; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):151-8. PubMed ID: 20136601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorapaxar expands antiplatelet options. Which patients may benefit from thrombin receptor antagonism?
    Duerschmied D; Bode C
    Hamostaseologie; 2012; 32(3):221-7. PubMed ID: 22777302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
    Rollini F; Tello-Montoliu A; Angiolillo DJ
    Future Cardiol; 2012 Jul; 8(4):503-11. PubMed ID: 22871190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.